SAN DIEGO, July 08, 2025--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, ...
SAN DIEGO, CA--(Marketwired - Feb 10, 2016) - Invivoscribe ® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has ...
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...
SAN DIEGO — Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and ...
IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. Invivoscribe, a ...
SAN DIEGO, May 19, 2020 /PRNewswire/ -- Invivoscribe to offer the LeukoStrat ® CDx FLT3 Mutation Assay as an FDA approved kit with analysis software. In 2017, Invivoscribe's LeukoStrat ® CDx FLT3 ...
Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® ...
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat ® KMT2A + MRD Assay and Software ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results